Product logins

Find logins to all Clarivate products below.


Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)

Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market is heavily genericized, and prescribers have many drug and drug class options, creating a high barrier to the uptake of novel branded agents. RAAS inhibitors and beta blockers are the first-line treatment for CHF, usually in combination with diuretics when fluid overload is present. The addition of a second- or third-line treatment is often needed to better manage the disease. The SGLT-2 inhibitors have become the next blockbuster drugs in the CHF market, and the use of Entresto (sacubitril / valsartan) is also expanding. This report provides important insight into how these agents are used in the management of CHF and how practices are evolving.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CHF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CHF patients?
  • How have SGLT-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of CHF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of CHF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: Pfizer, Merck & Co., Novartis, GSK, AstraZeneca, Johnson & Johnson innovative medicine, Eli Lilly, Boehringer Ingelheim, Amgen

Key drugs: ACE inhibitors, ARBs, beta blockers, MRAs, diuretics, CCBs, nitrates, ivabradine, vericiguat, Entresto (sacubitril / valsartan), SGLT-2 inhibitors

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…